Hematology

The approval is based on the results of the ACTIVATE and ACTIVATE-T phase 3 studies, Agios Pharmaceuticals says.

Dr Javier Pinilla-Ibarz leads the discussion on the role of targeted therapy over chemoimmunotherapy as a CLL therapeutic approach and shares NCCN Guidelines recommendations for the use of BTK inhibitors.

The application is based on data showing that lisocabtagene provides clinically meaningful and statistically significant improvement for those with relapsed or refractory large B-cell lymphoma.

The investigators identified this in 9% of relapsed cases of pediatric acute myeloid leukemia, but it also was present in primary samples.

Lisa Nodzon, PhD, ARNP, AOCNP, and Javier Pinilla-Ibarz, MD, PhD, provide insight on NCCN guideline recommendations for molecular testing in CLL and discuss the prevalence of testing for cytogenetic abnormalities.

Study shows that treatment with rituximab (Rituxan) for B-cell non-Hodgkin lymphoma prior to COVID-19 vaccination significantly lowered the number of patients who developed blocking antibodies for the virus.

Ixazomib (Ninlaro, Takeda) has been found to improve survival in patients with multiple myeloma who have not undergone autologous stem cell transplant.

Key opinion leaders discuss data from the MURANO trial on a fixed-duration therapy for relapsed/refractory chronic lymphocytic leukemia.

A hematology expert describes data from clinical trials on venetoclax-based therapies for chronic lymphocytic leukemia.

Drs Katie Tobon and Javier Pinilla-Ibarz explore the role of prognostic molecular testing in chronic lymphocytic leukemia and comment on challenges seen with referral patients that come from community practices.

Patients receiving brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in the frontline setting had a 41% reduction in the risk of death.

The trial studied 3 dosing regimens of asparaginase erwinia chrysanthemi (recombinant)-rywn, with cohort 1a receiving 25 mg/m2administered Monday and Wednesday and 50 mg/m2administered on Friday.

Granulomatosis is among a group of blood vessel disorders called vasculitis.

In a clinical trial, the median annualized bleeding rates for all bleeds was reduced from a historical median of 5 to an on-study median of 2.3, which is a 54.7% reduction.

Dr Anthony Perissinotti explains the new formulation of acalabrutinib for chronic lymphocytic leukemia presented at ASH 2021.

Dr Kirollos Hanna details clinical trial data on the use of zanubrutinib in treating chronic lymphocytic leukemia.

Lisa Nodzon, PhD, ARNP, AOCNP, and Javier Pinilla-Ibarz, MD, PhD, review challenges in CLL therapy, including cost barriers.

Further, the 1-year update suggests that Cohort 6 toxicity management strategy can improve certain AEs without compromising the activity of axicabtagene ciloleucel.

Umbralisib (Ukoniq) is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and relapsed or refractory follicular lymphoma.

The research team conducted a systematic review to collect the available published evidence on the topic and then combined the results using a process called meta-analysis.

Javier Pinilla-Ibarz, MD, PhD; Lisa Nodzon, PhD, ARNP, AOCNP; and Katie Tobon, PharmD, BCOP, describe the incidence of CLL and discuss factors that may increase the risk of disease.

Kovaltry temporarily replaces the missing clotting Factor VIII in patients with hemophilia A.

IMX-110 is a tissue-specific therapeutic designed to accumulate at intended therapeutic sites at 3 to 5 times the rate of conventional therapeutics.

The observed increase in patient age at the time of relapse makes the findings even more impressive because longer survival is typically associated with younger age at the time of relapse.

C-CAR039 showed positive efficacy and safety data in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.